

**DARBY &
DARBY**
Professional Corporation

**RECEIVED
CENTRAL FAX CENTER**

NOV 28 2005

NEW YORK
805 Third Avenue
New York, NY 10022
Tel: 212.527.7700
Fax: 212.527.7701

SEATTLE
1191 Second Avenue
Seattle, WA 98101-3404
Tel: 206.262.8900
Fax: 206.262.8901

INTELLECTUAL PROPERTY LAW

DATE: November 28, 2005

FILE #: 02427/1203347-US2

FACSIMILE NO.	RECIPIENT AND COMPANY	CONFIRMATION WILL FOLLOW
571-273-8300	Examiner Q. Janice Li, USPTO Art Unit 1633	No

FROM: Amy Klamm E-MAIL: agklamm@darbylaw.com

PHONE: 212-527-7692

NO. OF PAGES: 4
(including cover page)

COMMENTS: Proposed Claim Amendments for Serial Number 09/866,866 for
Telephone Discussion.

PLEASE RETURN TO

*** IF YOU DO NOT RECEIVE ALL PAGES, PLEASE TELEPHONE US IMMEDIATELY AT 212.527.7774**

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE SO THAT WE CAN ARRANGE FOR THE RETRIEVAL OF THIS DOCUMENT AT NO COST TO YOU. THANK YOU.

()

Docket No.: 02427/1203347-US2

Application No.: 09/866,866
Proposed Claims Showing Amendments

Claims 1-15 cancelled.

16. (Currently amended) An isolated antibody that ~~recognizes~~ binds to an extracellular portion of a Breast Cancer Resistance Protein (BCRP) selected from the group consisting of human or murine BCRP; wherein said the extracellular portion of the BCRP is in its natural conformation; wherein the antibody binds to living MCF-7 or 3T3 cells expressing BCRP on their surface; and wherein the antibody fails to bind to living MCF-7 cells that do not express BCRP.

Claims 17-21 (cancelled).

22. (Previously presented) The isolated antibody of claim 16 wherein the isolated antibody is monoclonal.

23. (Previously presented) The isolated antibody of claim 16 wherein the isolated antibody is chimeric.

24. (Previously presented) The isolated antibody of claim 23 wherein the antibody is humanized.

Claims 25-28 (cancelled).

29. (New) The isolated antibody of claim 16, operably attached to a detectable label.

30. (New) An immunodetection kit comprising, in suitable container means, the antibody according to claim 16 and an immunodetection reagent.

31. (New) An isolated antibody generated by
- (i) immunizing a mouse with 3T3 cells that express human or murine BCRP in its natural conformation on the cell surface;
 - (ii) selecting a hybridoma that secretes antibodies that bind to MCF-7 cells that express human or murine BCRP in its natural conformation on the cell surface, which antibodies do not bind to MCF-7 cells that do not express human or murine BCRP in its natural conformation on the cell surface; and
 - (iii) isolating an antibody from the hybridoma selected in step (ii).

32. (New) An isolated antibody generated by isolating an antibody from a hybridoma that secretes antibodies that bind to MCF-7 cells that express human or murine BCRP in its natural conformation on the cell surface, which antibodies do not bind to MCF-7 cells that do not express human or murine BCRP in its natural conformation on the cell surface, wherein the hybridoma is generated from a mouse immunized with 3T3 cells that express human or murine BCRP in its natural conformation on the cell surface.